Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.celrep.2021.109353 http://scihub22266oqcxt.onion/10.1016/j.celrep.2021.109353 34237283!8216847!34237283     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep 2021 ; 36 (2): 109353 Nephropedia Template TP {{tp|p=34237283|t=2021. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects |pdf=|usr=}}{{34237283}} gab.com Text Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects JO: Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=34237283 #FOAvip SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies. Twit Text FOAVip Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects ????Cell Rep http://www.kidney.de/pget.php?&tw=1&pmid=34237283 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34237283 #FOAvip English Wikipedia <ref>{{Cite pmid|34237283}}</ref> Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects #MMPMID34237283 Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L Cell Rep 2021[Jul]; 36 (2): 109353 PMID34237283show ga SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies. |Angiotensin-Converting Enzyme 2/chemistry/immunology[MESH] |Animals[MESH] |Antibodies, Monoclonal/*immunology[MESH] |Antibodies, Neutralizing/*immunology[MESH] |Antibodies, Viral/chemistry/immunology[MESH] |Binding Sites[MESH] |COVID-19/*immunology/*prevention & control[MESH] |Cell Line[MESH] |Cross Reactions[MESH] |Epitopes/immunology[MESH] |Female[MESH] |HEK293 Cells[MESH] |Humans[MESH] |Mice[MESH] |Neutralization Tests[MESH] |Protein Binding/immunology[MESH] |Protein Domains[MESH] |SARS-CoV-2/immunology[MESH]Isolation and characterization of cross-neutralizing coronavirus antib(epmc).pdf DeepDyve Pubget Overpricing